BigHat Biosciences Closes $75M Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
aiinsider ·
BigHat Biosciences has successfully closed a $75 million Series C financing round to advance its AI-driven protein therapeutics and agentic data platform. The investment was co-led by DFJ Growth and Premji Invest, with participation from major investors including Andreessen Horowitz, Amgen Ventures, and Eli Lilly, bringing the company's total funding to $223 million. This capital will support the expansion of BigHat’s autonomous experimental platform and accelerate its clinical pipeline, specifically for lead programs BHB810 and BHB299. BHB810 is currently in Phase 1 trials as one of the first AI-designed biologics to reach humans, while BHB299 is expected to enter human trials in 2027. The company continues to strengthen its partnerships with leading pharmaceutical firms such as Merck, Johnson & Johnson, and AbbVee. CEO Peyton Greenside emphasized that the funding enables the scaling of their integrated learning loop between molecular design and experimental validation. BigHat aims to address the common failure points of biologics by engineering optimal properties during the earliest stages of design.
aiinsider